Background: A brief bedside test has recently been introduced by Hoche et al. (Brain, 2018) to screen for the Cerebellar Cognitive Affective Syndrome (CCAS) in patients with cerebellar disease. Objective: This multicenter study tested the ability of the CCAS-Scale to diagnose CCAS in individual patients with common forms of hereditary ataxia. Methods: A German version of the CCAS-Scale was applied in 30 SCA3, 14 SCA6 and 20 FRDA patients, and 64 healthy participants matched for age, sex, and level of education. Based on original cut-off values, the number of failed test items was assessed, and CCAS was considered possible (one failed item), probable (two failed items) or definite (three failed items). In addition a total sum raw score was calculated. Results: On a group level, failed items were significantly higher and total sum scores were significantly lower in SCA3 patients compared to matched controls. SCA6 and FRDA patients performed numerically below controls, but respective group differences failed to reach significance. The ability of the CCAS-Scale to diagnose CCAS in individual patients was limited to severe cases failing three or more items. Milder cases failing one or two items showed a great overlap with the performance of controls exhibiting a substantial number of false-positive test results. The word fluency test items differentiated best between patients and controls. Conclusions: As a group, SCA3 patients performed below the level of SCA6 and FRDA patients, possibly reflecting additional cerebral involvement. Moreover, the application of the CCAS-Scale in its present form results in a high number of false-positive test results, that is identifying controls as patients, reducing its usefulness as a screening tool for CCAS in individual patients.
Bibliographical noteFunding Information:
Open Access funding enabled and organized by Projekt DEAL. This work was supported by the German Heredo-Ataxia Society (Deutsche Heredo-Ataxie-Gesellschaft e.V.), “Freunde und Förderer der Neurologie der Universitätsmedizin Essen” and a scholarship of UMEA/DFG (University Medicine Essen Clinician Scientist Academy—a program funded by Deutsche Forschungsgemeinschaft, German Research Foundation; FU356/12-1) awarded to A.T. The study was also supported by the DFG grant N° 441409627, as part of the PROSPAX consortium under the frame of EJP-RD, the European Joint Programme on Rare Diseases, under the EJP-RD COFUND-EJP N° 825575 awarded to M.S. and D.T. as an associated partner. A.T. received research grants from the German Heredo-Ataxia Society (Deutsche Heredo-Ataxie-Gesellschaft e.V.), “Freunde und Förderer der Neurologie der Universitätsmedizin Essen” and a scholarship of UMEA/DFG (University Medicine Essen Clinician Scientist Academy—a program funded by the German Research Foundation; FU356/12-1). J.F. None. P.S. None. K.R. has received grants from the German Federal Ministry of Education and Research (BMBF 01GQ1402, 01DN18022), the German Research Foundation (IRTG 2150), Alzheimer Forschung Initiative e.V. (NL-18002CB), Friedreich’s Ataxia Research Alliance (FARA) and honoraria for presentations or advisory board from Biogen and Roche. I.D. None. M.B. None. J.Kr. None. H.J. None. JE.A. None. M.M. received a research grant from Deutsche Forschungsgemeinschaft (DFG; German Research Foundation). S.E. None. R.VdV. None. J.M. None. G.B. None. J.Ko. None. M.S. received consultancy honoraria from Ionis Pharmaceuticals (Carlsbad, California, USA), Jansen Pharmaceuticals (Beerse, Belgium) and Orphazyme Pharmaceuticals (Copenhagen, Denmark). S.R. None. D.T. received research grants from Deutsche Forschungsgemeinschaft (DFG; German Research Foundation), the European Union, and the Bernd-Fink-Foundation.
© 2022, The Author(s).
- Bedside test